Related Experiment Video
Updated: Mar 1, 2026
13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
18.2K
Geroprotectors: A Unified Concept and Screening Approaches
Alexey Moskalev1,2,3, Elizaveta Chernyagina2, Anna Kudryavtseva1
11Laboratory of postgenomic studies, Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Moscow, 119991, Russia.
Aging and Disease
|June 6, 2017
Summary
Geroprotectors slow aging in model organisms, but none are on the market due to a lack of unified concepts. A new classification based on homeostatic capacity could standardize anti-aging drug development.
Area of Science:
- Biomedicine
- Gerontology
- Pharmacology
Background:
- Geroprotector discovery is a rapidly advancing field with over 200 identified compounds.
- Despite progress, no geroprotectors are currently available on the market.
- A lack of a unified scientific concept hinders geroprotector development and comparison.
Purpose of the Study:
- To review existing geroprotector classifications and characteristics.
- To propose a new geroprotector concept based on maintaining homeostatic capacity.
- To discuss current screening approaches for identifying new geroprotectors.
Main Methods:
- Review of existing literature on geroprotector classification and aging theories.
- Analysis of classification systems based on survival effects, mechanisms, and aging theories.
- Proposal of a new conceptual framework centered on homeostatic capacity.
Main Results:
- Existing classifications have limitations in unifying research efforts.
- Aging is characterized by the exponential decline of homeostatic capacity.
- A homeostatic capacity-based concept offers a unified framework for geroprotector identification.
Conclusions:
- A unified concept and classification system for geroprotectors are essential.
- Standardizing geroprotector identification will facilitate data comparison and drug development.
- Focusing on homeostatic capacity provides a promising direction for future anti-aging research.
Related Concept Videos
02:46Genetic Screens
5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
285
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
285
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
01:15Drug Dosing: Geriatric Patients
328
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
328
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53